|
1
|
Koyama K, Ebata T, Yokoyama Y, Igami T,
Sugawara G, Mizuno T, Yamaguchi J and Nagino M: Recurrence after
curative-intent resection of perihilar cholangiocarcinoma: Analysis
of a large cohort with a close postoperative follow-up approach.
Surgery. 163:732–738. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Cillo U, Fondevila C, Donadon M, Gringeri
E, Mocchegiani F, Schlitt HJ, Iizermans JNM, Vivarelli M,
Zieniewicz K, Olde Damink SWM and Groot Koerkamp B: Surgery for
cholangiocarcinoma. Liver Int. 39 (Suppl 1):S143–S155.
2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Nagino M, Ebata T, Yokoyama Y, Igami T,
Sugawara G, Takahashi Y and Nimura T: Evolution of surgical
treatment for perihilar cholangiocarcinoma: A single-center 34-year
review of 574 consecutive resections. Ann Surg. 258:129–140.
2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Valle J, Wasan H, Palmer DH, Cunningham D,
Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira
SP, et al: Cisplatin plus gemcitabine versus gemcitabine for
biliary tract cancer. N Engl J Med. 362:1273–1281. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Horgan AM, Amir E, Walter T and Knox JJ:
Adjuvant therapy in the treatment of biliary tract cancer: A
systematic review and meta-analysis. J Clin Oncol. 30:1934–1940.
2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Monson JR, Donohue JH, Gunderson LL,
Nagorney DM, Bender CE and Wieand HS: Intraoperative radiotherapy
for unresectable cholangiocarcinoma-the mayo clinic experience.
Surg Oncol. 1:283–290. 1992.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kamada T, Tsujii H, Blakely EA, Debus J,
De Neve W, Durante M, Jäkel O, Mayer R, Orecchia R, Pötter R, et
al: Carbon ion radiotherapy in Japan: An assessment of 20 years of
clinical experience. Lancet Oncol. 16:e93–e100. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ohkawa A, Mizumoto M, Ishikawa H, Abei M,
Fukuda K, Hashimoto T, Sakae T, Tsuboi K, Okumura T and Sakurai H:
Proton beam therapy for unresectable intrahepatic
cholangiocarcinoma. J Gastroenterol Hepatol. 30:957–963.
2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Makita C, Nakamura T, Takada A, Takayama
K, Suzuki M, Ishikawa Y, Azami Y, Kato T, Tsukiyama I, Kikuchiet Y,
et al: Clinical outcomes and toxicity of proton beam therapy for
advanced cholangiocarcinoma. Radiat Oncol. 9(26)2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hong TS, Wo JY, Yeap BY, Ben-Josef E,
McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L,
et al: Multi-institutional phase II study of high-dose
hypofractionated proton beam therapy in patients with localized,
unresectable hepatocellular carcinoma and intrahepatic
cholangiocarcinoma. J Clin Oncol. 34:460–468. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bush DA, Smith JC, Slater JD, Volk ML,
Reeves ME, Cheng J, Grove R and de Vera ME: Randomized clinical
trial comparing proton beam radiation therapy with transarterial
chemoembolization for hepatocellular carcinoma: Results of an
interim analysis. Int J Radiat Oncol Biol Phys. 95:477–482.
2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Brierley JD, Gospodarowicz MK and
Wittekind C (eds): TNM Classification of Malignant Tumors. 8th
edition. In: Union for International Cancer Control.
Wiley-Blackwell, p272, 2017.
|
|
13
|
de Jong MC, Nathan H, Sotiropoulos GC,
Paul A, Alexandrescu S, Marques H, Pulitano C, Barroso E, Clary BM,
Aldrighetti L, et al: Intrahepatic cholangiocarcinoma: An
international multi-institutional analysis of prognostic factors
and lymph node assessment. J Clin Oncol. 29:3140–3145.
2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mizumoto M, Sugahara S, Nakayama H, Hashii
H, Nakahara A, Terashima T, Okumura T, Tsuboi K, Tokuuye K and
Sakurai H: Clinical results of proton-beam therapy for
locoregionally advanced esophageal cancer. Strahlenther Onkol.
186:482–488. 2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Terashima K, Demizu Y, Hashimoto N, Jin D,
Mima M, Fujii O, Niwa Y, Takatori K, Kitajima N, Sirakawaet S, et
al: A phase I/II study of gemcitabine-concurrent proton
radiotherapy for locally advanced pancreatic cancer without distant
metastasis. Radiother Oncol. 103:25–31. 2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bush DA, Kayali Z, Grove R and Slater JD:
The safety and efficacy of high-dose proton beam radiotherapy for
hepatocellular carcinoma: A phase 2 prospective trial. Cancer.
117:3053–3059. 2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Schineider RA, Vitolo V, Albertini F, Koch
T, Ares C, Lomax A, Goitein G and Hug EB: Small bowel toxicity
after high dose spot scanning-based proton beam therapy for
paraspinal/retroperitoneal neoplasms. Strahlenther Onkol.
189:1020–1025. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kamata T: Clinical evidence of particle
beam therapy (carbon). Int J Clin Oncol. 17:85–88. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ohno T: Particle radiotherapy with carbon
ion beams. EPMA J. 4(9)2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kazuki T: Radiation therapy and particle
radiotherapy using proton or carbon-ion beam for biliary duct
cancer. Journal of Japan Biliary Association. 32:114–123. 2018.(In
Japanese).
|
